Making Treatment Guideline Recommendations in Chronic Kidney Disease and Type 2 Diabetes More Accessible to Primary Care Providers in the United States
Source : https://pubmed.ncbi.nlm.nih.gov/38712604/
Clinical practice guidelines for the management of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) are designed to assist healthcare professionals with clinical decision making by providing recommendations...
Researchers explore reasons behind the low level of awareness and poor uptake of published evidence-based care approaches to the optimal care of patients with T2D and CKD.
With up to 23 years of follow-up of 3 large prospective cohorts of middle-aged and older men and women, self-reported melatonin supplement use was not associated with risk of type 2 diabetes or CVD.
Time-to-Event Genome-Wide Association Study for Incident Cardiovascular Disease in People With Type 2 Diabetes
OBJECTIVE. To identify genetic risk factors for incident cardiovascular disease (CVD) among people with type 2 diabetes (T2D).RESEARCH DESIGN AND METHODS.
Researchers identified 3 novel genetic loci: rs147138607 (near CACNA1E/ZNF648), rs11444867 (near HS3ST1), and rs335407 (near TFB1M/NOX3).
Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38652878/
Our findings suggest therapy-related genetic risks contribute to the increased T2D burden among non-Hispanic Black childhood cancer survivors. Additional study of how therapy-related genetic susceptibility contributes to this disparity is...
Therapy-related genetic risks contribute to the increased burden of type 2 diabetes among non-Hispanic Black pediatric survivors of cancer.
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 2 Diabetes After 26 Weeks' Treatment: a Randomized Open Label Study
Source : https://pubmed.ncbi.nlm.nih.gov/38558508/
GL Glargine was similar to Lantus® in terms of immunogenicity, efficacy, and safety, based on the current study.
GL glargine was similar in terms of immunogenicity, efficacy, and safety, based on the current study.